Phathom Pharmaceuticals, Inc. (PHAT)

NASDAQ: PHAT · IEX Real-Time Price · USD

10.25

-0.56 (-5.18%)

At close: Jul 2, 2024, 4:00 PM

10.80

+0.55 (5.37%)

After-hours: Jul 2, 2024, 5:53 PM EDT

Phathom Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Revenue	0.68	0	0	0	0	Upgrade
Cost of Revenue	0.17	0	0	0	0	Upgrade
Gross Profit	0.52	0	0	0	0	Upgrade
Selling, General & Admin	117.93	101	62.74	27.52	6.94	Upgrade
Research & Development	49.9	71.44	72.34	98.15	20.37	Upgrade
Other Operating Expenses	0	0	0	0	78.9	Upgrade
Operating Expenses	167.83	172.44	135.08	125.67	106.22	Upgrade
Operating Income	-167.31	-172.44	-135.08	-125.67	-106.22	Upgrade
Interest Expense / Income	41.97	27.31	6.79	4.58	4.18	Upgrade
Other Expense / Income	-7.69	-2.02	2.02	-1.18	144.74	Upgrade
Pretax Income	-201.59	-197.72	-143.88	-129.07	-255.13	Upgrade
Net Income	-201.59	-197.72	-143.88	-129.07	-255.13	Upgrade
Shares Outstanding (Basic)	51	39	37	33	11	Upgrade
Shares Outstanding (Diluted)	51	39	37	33	11	Upgrade
Shares Change	31.11%	5.72%	11.36%	192.32%	87.83%	Upgrade
EPS (Basic)	-3.93	-5.05	-3.89	-3.88	-22.45	Upgrade
EPS (Diluted)	-3.93	-5.05	-3.89	-3.88	-22.45	Upgrade
Free Cash Flow	-139.21	-147.57	-148.79	-70.73	-36.64	Upgrade
Free Cash Flow Per Share	-2.71	-3.77	-4.02	-2.13	-3.22	Upgrade
Gross Margin	75.51%	-	-	-	-	Upgrade
Operating Margin	-24532.55%	-	-	-	-	Upgrade
Profit Margin	-29558.94%	-	-	-	-	Upgrade
Free Cash Flow Margin	-20412.61%	-	-	-	-	Upgrade
EBITDA	-159.05	-169.8	-136.57	-124.16	-250.95	Upgrade
EBITDA Margin	-23320.97%	-	-	-	-	Upgrade
Depreciation & Amortization	0.58	0.62	0.52	0.32	0.01	Upgrade
EBIT	-159.62	-170.42	-137.1	-124.49	-250.95	Upgrade
EBIT Margin	-23405.28%	-	-	-	-	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).